Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.

Market Access Pricing Strategies Pricing Debate

Latest From Pricing Debate

Medicare May Require Part D Plans To Provide Point-of-Sale Rebates

CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.

Pricing Debate Pharmacy Benefit Management

Mehta Analysis: Race To Harness Data Will Revolutionize PBM System

Data and intelligence will drive revolutionary changes in healthcare, and today's power brokers will need to adapt. Viren Mehta, founding partner of Mehta Partners LLC, considers how business consolidation in the complex US pharma market reflects the race to tap as yet under-exploited data troves, and how the resulting exploitation of those data may benefit a broader set of stakeholders.

Pharmacy Benefit Management Commercial

OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'

Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.

Pricing Debate Reimbursement

US Pricing Squeeze Clouds Sun Pharma Q2; Site Re-Inspection Critical

Further evidence of the impact of pricing pressure in the US was provided when Sun Pharma reported a sharp fall in profits in Q2 (although it beat the expectations of some analysts). Sun also expects a delay in EU approval for its late stage psoriasis asset, tildrakizumab, but US approval timelines appear unchanged, at least for now.

Sales & Earnings India

HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

Pricing Debate Government Payers

FDA Prioritizes ANDAs Ready For Launch After 180-Day Exclusivity Expires

In effort to speed competition and lower drug prices, US regulator will prioritize review of generic drug applications likely to be ready for approval on or shortly after the expiration of first-filer's exclusivity; experts say the move appears to formalize what once had been an informal Office of Generic Drugs policy.

Generic Drugs Pricing Debate

Beyond Pay-For-Delay: US FTC Digs Deeper On Barriers To Generic Competition

FTC Acting Chairman Ohlhausen predicts agency will continue to focus on competition issues involving barriers to generics but says 'we need to learn more about how these markets are working today.'

Pricing Debate Legal Issues

Mehta Analysis: The Tangled Web Of PBMs

Pharmacy Benefit Managers are a key part of the medicines market in the US, but their role is complex. Viren Mehta, founding partner of Mehta Partners, LLC considers how their business model has evolved over the years, where it is headed, and how PBMs impact others in the healthcare ecosystem.

Pharmacy Benefit Management Policy

Orphan Drug Pricing Doesn't Drive Healthcare Costs, NORD Argues

QuintilesIMS Institute study funded by the National Organization for Rare Disorders concludes orphan drugs accounted for only 7.9% of US total drug spending in 2016, bolstering advocacy group's view that rare disease treatments are not responsible for rising healthcare costs. US FDA analysis finds most orphan drugs do not expand their labeled indications into non-rare disease settings.

Rare Diseases Legislation
See All
UsernamePublicRestriction

Register